SCRI Development Innovations
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, SCRI Development Innovations sits in the top decile of US sponsors by registered trial count (#191 of 15,742 sponsors by registered trial count).
SCRI Development Innovations: 146 sponsored US clinical trials, 5 recruiting.
SCRI Development Innovations sponsors 146 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 125 completed. 2 of these trials are in Phase 3-4 (later-stage) and 134 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 4 trials.
Top-decile sponsor footprint
SCRI Development Innovations ranks in the top decile of sponsors by registered trial count (#191 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
125 of 141 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
146 total, page 2 of 3
Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC
NCT01042288
A Retrospective Cohort Study of Infusion Reactions Due to Vectibix
NCT01156090
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
NCT01121939
Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
NCT01056276
SCRI Tissue Testing Registry
NCT00965861
Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma
NCT01029730
Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
NCT00894504
Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
NCT01014351
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
NCT01027598
Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma
NCT01035658
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
NCT00972335
A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer
NCT01076504
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
NCT01033032
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
NCT00960297
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
NCT00915603
Trial of Poor Performance Status Patients (ToPPS)
NCT00892710
Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
NCT00906282
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
NCT00887575
Review of Molecular Profiling-Real Time Polymerase Chain Reaction (Rt-Pcr) in Unknown Primary Cancer
NCT00876408
Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma
NCT00876382
Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer
NCT00866905
Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer
NCT00825734
Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
NCT00821886
Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas
NCT00837031
RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM
NCT00805961
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
NCT00789581
Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer
NCT00876070
PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors
NCT00759928
Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer
NCT00741988
Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
NCT00731211
Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
NCT00737243
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
NCT00633594
Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer
NCT00695292
LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients
NCT00632489
Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer
NCT00629499
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
NCT00609804
Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
NCT00600015
Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors
NCT00613145
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
NCT00536341
Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting
NCT00877045
RAD001 Plus Bevacizumab in Metastatic Melanoma
NCT00591734
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma
NCT00550277
LBH589 in Refractory Myelodysplastic Syndromes (MDS)
NCT00594230
LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors
NCT00556088
Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC
NCT00621049
Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients
NCT00536575
CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas
NCT00540579
LBH589 and Gemcitabine in the Treatment of Solid Tumors
NCT00550199
Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer
NCT00544167
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
NCT00545766
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 29 |
| Phase 2 | 105 |
| Phase 3 | 2 |
What is open in the SCRI Development Innovations pipeline
5 recruiting of 146 indexed (3% open); 125 completed (86%).
Phase mix: 2 late (III/IV) vs 134 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
SCRI Development Innovations: open-pipeline peers nationwide
Peers matched on 146 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
SCRI Development Innovations sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 146 trials (± recruiting share)
- HealthPartners Institute · 146 trials · 8% recruiting
- Mylan Pharmaceuticals · 146 trials · 1% recruiting
- Forest Laboratories · 145 trials · 0% recruiting
- National Institute of Environmental Health Sciences (NIEHS) · 145 trials · 10% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Medtronic MiniMed · 3% recruiting · 29 trials
- Sandoz · 3% recruiting · 29 trials
- Sonova · 3% recruiting · 29 trials
- USDA Beltsville Human Nutrition Research Center · 3% recruiting · 29 trials
Related
What to do with this SCRI Development Innovations page
146 registered trials is a research-attention snapshot, not an endorsement of SCRI Development Innovations or any single study.
- 5 of SCRI Development Innovations's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition SCRI Development Innovations studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
SCRI Development Innovations pipeline card: 146 registered trials from official public datasets.Report a data error.